FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Panel Backs Mesoblast BLA for Graft Versus Host Disease

[ Price : $8.95]

FDAs Oncologic Drugs Advisory Committee votes nine to one in favor of approving a Mesoblast BLA for Ryoncil (remestemcell-L) as a ...

Safety and Performance Pathway Criteria

[ Price : $8.95]

FDA issues the first two guidances with performance criteria for two medical device types to support the safety and performance-ba...

Assessing Clinical Benefit with a Focus on Pain

[ Price : $8.95]

CDER researchers discuss the regulatory approach to assessing clinical benefit with a focus on pain.

FDA Position on Reporting Threshold in USP Monographs

[ Price : $8.95]

FDA explains why it believes USP should not include disregard limits/reporting thresholds in any monograph revisions.

Medical Device Covid FAQs

[ Price : $8.95]

FDA issues two FAQ documents on medical device importing and registration/listing during the Covid-19 pandemic.

RapidAI Gains Clearance for Large Vessel Occlusions

[ Price : $8.95]

FDA clears a RapidAI 510(k) for the Rapid LVO for detecting suspected large vessel occlusions.

FDA Clears T-Line Hernia Mesh

[ Price : $8.95]

FDA clears Deep Blue Medical Advances T-Line hernia mesh.

Novartis sBLA for Self-administration Xolair

[ Price : $8.95]

FDA accepts a Novartis supplemental BLA for a new self-administration option for Xolair (omalizumab).

FDA Accepts TG Theraputics NDA for Lymphoma

[ Price : $8.95]

FDA accepts a TG Therapeutics NDA for umbralisib, a once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon for treating ce...

Workshop on New Drugs Regulatory Program Modernization

[ Price : $8.95]

Federal Register notice: FDA announces a10/30 public workshop entitled New Drugs Regulatory Program Modernization: Implementation ...